Pharmaceuticals

A new report reveals a massive strategic shift in obesity care. Pharma giants are pouring billions into FGF21, a new drug class aiming beyond weight loss.

UFC GYM's new PWR Clinics signal a tectonic shift in the wellness industry. Is this the future of fitness or a high-stakes bet on a regulatory minefield?

Beyond a simple conference, Tsingke Biotech's recent salon was a strategic play to position itself as the linchpin in China's shift to biotech innovation.

A new FDA pilot program with Japan's Kyowa Kirin aims to slash drug approval times. It's an operational innovation that could fix U.S. supply chains.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?

A new collaboration between AustinPx and Thermo Fisher is scaling up KinetiSol, a breakthrough tech that makes insoluble drugs viable, promising greener paths to new therapies.

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

The world's only lupus-focused fund is betting on a new model blending VC rigor with patient-led strategy. But can this ambitious structure deliver real progress?

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

With a new U.S. patent, Quoin Pharmaceuticals reinforces its strategy for QRX003, a potential first-ever treatment for devastating Netherton Syndrome.

As demand for its blockbuster drugs soars, Novo Nordisk turns to India's Shantha Biologics in a strategic deal that highlights a global supply chain shift.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

Will Therapeutics lands $3.5M to develop the first targeted drug for anorexia, aiming to treat the biological roots of compulsion. A breakthrough in the making?

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.